Results 11 to 20 of about 1,994,731 (278)
Breast Cancer: Rank Ligand Inhibition. [PDF]
Breast Care (Basel), 2010 Breast cancer and bone health are closely linked. Early menopause induced by gonadotropin-releasing hormone analogues or chemotherapy as well as aromatase inhibitors reduce oestrogen levels, thereby causing cancer treatment-induced bone loss (CTIBL). Furthermore, bone metastases are commonly found in advanced disease. Current treatment options for bone
Bartsch R +3 more
europepmc +4 more sources
Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects [PDF]
Stroke, 2009 Background and Purpose— Homocysteine has been linked to increased risk of ischemic stroke and other cardiovascular events. Matrix degradation and inflammation play an important role in these disorders, and we have demonstrated increased levels of matrix-degrading enzymes and inflammatory cytokines in
Marit S, Nenseter +8 more
openaire +3 more sources
NIP45 negatively regulates RANK ligand induced osteoclast differentiation. [PDF]
J Cell Biochem, 2012 AbstractReceptor activator of NF‐κB ligand (RANKL)‐RANK receptor signaling to induce NFATc1 transcription factor is critical for osteoclast differentiation and bone resorption. RANK adaptor proteins, tumor necrosis factor receptor‐associated factors (TRAFs) play an essential role in RANKL signaling.
Shanmugarajan S +3 more
europepmc +4 more sources
Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells. [PDF]
J Cell Physiol, 2018 Sambandam Y +6 more
europepmc +2 more sources
The role of RANK-ligand inhibition in cancer: the story of denosumab. [PDF]
Oncologist, 2011 The bone is a very common site of metastasis in patients with advanced cancer. Skeletal metastases are most common in breast and prostate cancer, but virtually any advanced cancer may disseminate to the bone.
Castellano D +5 more
europepmc +2 more sources
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. [PDF]
Clin Interv Aging, 2012 Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the ...
Yee AJ, Raje NS.
europepmc +2 more sources
RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. [PDF]
J Cell Biochem, 2016 Sambandam Y +3 more
europepmc +2 more sources
Experimental Physiology, 2020 What is the central question of this study? What is the role of miR‐143‐3p during human dental pulp stem cell (hDPSC) differentiation. What is the main finding and its importance?
Chang-wei Yang +7 more
semanticscholar +1 more source
RANK and RANK Ligand Expression in Parotid Gland Carcinomas [PDF]
Applied Immunohistochemistry & Molecular Morphology, 2018 Recently, it has been reported that deregulation of the receptor activator of NFkB ligand (RANKL)/RANK signaling axis results in salivary gland tumor development in a mouse transgenic model. The aim of this study was to ascertain RANKL and RANK protein expression in a series of primary parotid gland carcinomas and to correlate it with clinicopathologic
Franchi A +6 more
openaire +4 more sources
Genetically Encoded Photo-cross-linkers Map the Binding Site of an Allosteric Drug on a G Protein-Coupled Receptor [PDF]
, 2012 G protein-coupled receptors (GPCRs) are dynamic membrane proteins that bind extracellular molecules to transduce signals. Although GPCRs represent the largest class of therapeutic targets, only a small percentage of their ligand-binding sites are ...
Abrol, Ravinder +5 more
core +1 more source